HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

889.898

-24.229-2.65%

Number of Gainers:2

Number of Losers:14

Number of Flat:1

PE:- -

High:930.232

Open:914.556

Low:889.821

Close:914.244

Volume:231.77M

Turnover:1.86B

Market Cap:602.80B

Float Cap:497.79B

Loading ...

CSPC Pharma's JMT206 Injection Ib Phase Trial for Weight Management in Overweight or Obese Adults Officially Launches at First Site in China

CSPC Pharma's Recombinant Shingles Vaccine SYS 6052 Gains US Clinical Trial Approval

Cspc Pharmaceutical's Recombinant Herpes Zoster Vaccine (Sys6052) Obtains FDA Clinical Trial Approval in U.S.

CSPC Pharmaceutical - Phase Ib Trial to Evaluate Jmt206 Injection as Monotherapy or with Semaglutide in Obesity

THOMSON REUTERS

CSPC Pharmaceutical - Phase Ib Clinical Trial of Jmt206 Injection for Weight Management in Adult Patients Initiated at First Study Centre in China

THOMSON REUTERS

Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, "Buy" Rating Maintained

AH Premium Statistics for September 29

Sino Biopharm Unit CTTQ Presents Phase 3 APEX-Breast01 Data for Tqb2102 in HER2-Low Breast Cancer at ESMO 2026

Sisram Medical Proposes New Sublicensing, Promo Services Pacts with Fosun Pharma's Unit

MT Newswires Live

Ping An Healthcare to Renew Agreements with Ping An Life Insurance

MT Newswires Live

Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial

MT Newswires Live

GENFLEET-B (02595) Shares Surge Nearly 8% in Early Trading; Investigational Oral Drug Proposed for Breakthrough Therapy Designation

Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment

Estimating the Value of PL-5: How Much Is This Wound Infection Candidate Worth for HK-Listed Aspirant Prolytix?

Prairie Pharmaceutical's Second Attempt at HKEX Listing: Cash Crunch, Billion-Yuan Redemption Liability Looming, Core Product Commercialization Faces Multiple Hurdles

Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study

Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis

THOMSON REUTERS

Pharma ETF Rebounds Against the Tide as Device Giants Provide Support, Defensive Strength Draws Attention

CSPC Pharma Gets China Nod for Tumor Drug Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BK1515/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":890.0149,"timestamp":1791442116182,"preClose":914.24426,"halted":0,"volume":231754543,"delay":0,"changeRate":-0.026502,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-24.22937,"latestTime":"10-08 14:48:36","open":914.5563,"high":930.2323,"low":889.8213,"amount":1862071152,"amplitude":0.044202,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791447000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791423000000,1791432000000],[1791435600000,1791446400000]],"pbRate":1.386435,"peRate":17.966934,"turnoverRate":0.003175,"increases":2,"decrements":14,"flats":1,"marketCap":602804106176,"floatMarketCap":497789380160},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":930.2323,"amplitude":0.044202,"preClose":914.24426,"low":889.8213,"pbRate":"1.386435","latestPrice":889.8975,"volume":231771293,"delay":0,"open":914.5563,"prevYearClose":1190.107,"prevWeekClose":903.801,"prevMonthClose":925.469,"prevQuarterClose":925.469,"fiveDayClose":925.469,"twentyDayClose":912.778,"sixtyDayClose":917.488,"secType":"PLATE","market":"HK","turnoverRate":0.003175,"peRate":17.966934,"marketCap":602793835456,"floatMarketCap":497786779712,"timestamp":1791442120594,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":2,"down":14,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1195483618","title":"CSPC Pharma's JMT206 Injection Ib Phase Trial for Weight Management in Overweight or Obese Adults Officially Launches at First Site in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1195483618","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195483618?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:09","pubTimestamp":1790676579,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited (01093) has announced that the Phase Ib clinical trial (JMT206–003) of its self-developed JMT206 Injection for weight management in overweight or obese adult...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1226287529.USD","IE00BZ08YR35.GBP","LU1226288253.USD","LU1807302812.USD","IE00B543WZ88.USD","LU0072913022.USD","LU1226287792.SGD","LU1951186391.HKD","01093","LU0326950275.SGD","BMED","KURE","IBBQ","IE00B031HY20.USD","LU1960683339.HKD","PSYK","LU0067412154.USD","IBBJ","LU0880133367.SGD","SG9999004220.SGD","LU1993786604.SGD","BK1191","LU1226287875.USD","BK1521","LU2039709279.SGD","LU0501845795.SGD","LU1813983027.USD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1328277881.USD","LU1008478684.HKD","LU0315179316.USD","LU1152091168.USD","HK0000165453.HKD","IE0008368742.USD","LU1152091754.HKD","MDTX","LU0140636845.USD","LU0314109678.HKD","BK1515","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154469835","title":"CSPC Pharma's Recombinant Shingles Vaccine SYS 6052 Gains US Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1154469835","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154469835?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:08","pubTimestamp":1790676512,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its Class 1 preventive biological product, the recombinant shingles vaccine (SYS 6052), has received approval from the US Food and Drug Administration (FDA) to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","LU0880133367.SGD","LU1226287792.SGD","IE0008369823.USD","IE0008368742.USD","LU1152091754.HKD","LU1951186391.HKD","LU0315179316.USD","LU1152091168.USD","IBBJ","IE00B543WZ88.USD","LU0326950275.SGD","LU0072913022.USD","LU0314109678.HKD","LU0067412154.USD","LU1807302812.USD","LU0501845795.SGD","BK1515","KURE","LU1993786604.SGD","LU1226287875.USD","IE00B031HY20.USD","MDTX","LU1008478684.HKD","LU1226288170.HKD","HK0000165453.HKD","IE00BZ08YR35.GBP","IBBQ","LU2039709279.SGD","LU0140636845.USD","LU1960683339.HKD","01093","BK1191","IE00B5MMRT66.SGD","LU1226287529.USD","BMED","PSYK","SG9999004220.SGD","BK1521","LU1328277881.USD","LU1226288253.USD","LU1813983027.USD","IE00BZ08YS42.EUR","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671133192","title":"Cspc Pharmaceutical's Recombinant Herpes Zoster Vaccine (Sys6052) Obtains FDA Clinical Trial Approval in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2671133192","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671133192?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:07","pubTimestamp":1790676434,"startTime":"0","endTime":"0","summary":"BRIEF-Cspc Pharmaceutical's Recombinant Herpes Zoster Vaccine (Sys6052) Obtains FDA Clinical Trial Approval In U.S.Sept 29 (Reuters)-CSPC PHARMACEUTICAL GROUP LIMITED1093.HK:PHARMA'S RECOMBINANT HERPE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328277881.USD","IE0008368742.USD","IE00B031HY20.USD","LU1813983027.USD","LU1993786604.SGD","LU0501845795.SGD","LU0067412154.USD","LU1226288253.USD","IE0008369823.USD","IE00B543WZ88.USD","LU1226287875.USD","LU0140636845.USD","LU2039709279.SGD","LU1008478684.HKD","SG9999004220.SGD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","HK0000165453.HKD","BK1191","LU0072913022.USD","LU0315179316.USD","LU1226287792.SGD","IE00BZ08YR35.GBP","LU1951186391.HKD","IE00BZ08YS42.EUR","LU0314109678.HKD","01093","KURE","LU1226287529.USD","LU1152091754.HKD","LU1226288170.HKD","BK1521","LU0880133367.SGD","BK1515","LU1152091168.USD","LU1807302812.USD","LU0326950275.SGD","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671133372","title":"CSPC Pharmaceutical - Phase Ib Trial to Evaluate Jmt206 Injection as Monotherapy or with Semaglutide in Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671133372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671133372?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:05","pubTimestamp":1790676302,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L01V:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1328277881.USD","LU0326950275.SGD","IE0008368742.USD","LU1226287792.SGD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1226288253.USD","LU1993786604.SGD","IE0008369823.USD","LU1008478684.HKD","01093","LU1152091754.HKD","LU0501845795.SGD","IE00B031HY20.USD","LU1960683339.HKD","LU0314109678.HKD","LU0140636845.USD","LU1951186391.HKD","LU1226288170.HKD","LU1152091168.USD","BK1191","HK0000165453.HKD","LU2039709279.SGD","LU0880133367.SGD","IE00B5MMRT66.SGD","BK1515","LU0067412154.USD","LU0315179316.USD","SG9999004220.SGD","IE00B543WZ88.USD","KURE","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1226287875.USD","LU1807302812.USD","BK1521","LU1813983027.USD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671133352","title":"CSPC Pharmaceutical - Phase Ib Clinical Trial of Jmt206 Injection for Weight Management in Adult Patients Initiated at First Study Centre in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2671133352","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671133352?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:05","pubTimestamp":1790676302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L01V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000165453.HKD","SG9999004220.SGD","KURE","BK1521","LU0501845795.SGD","LU1008478684.HKD","LU1328277881.USD","IE00B031HY20.USD","IE0008368742.USD","BK1191","LU1226288253.USD","LU2039709279.SGD","LU1226287875.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","IE00BZ08YR35.GBP","LU0315179316.USD","LU1226287529.USD","LU1951186391.HKD","LU0072913022.USD","IE00B5MMRT66.SGD","01093","LU1226287792.SGD","IE00B543WZ88.USD","LU1993786604.SGD","LU0326950275.SGD","LU1960683339.HKD","IE00BZ08YT58.USD","LU0067412154.USD","LU1152091168.USD","LU1152091754.HKD","LU1226288170.HKD","BK1515","LU0140636845.USD","LU1813983027.USD","LU0314109678.HKD","LU1807302812.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147221461","title":"Citi: Sino Biopharmaceutical and STADA Form Biosimilar Strategic Partnership, \"Buy\" Rating Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=1147221461","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147221461?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:54","pubTimestamp":1790672068,"startTime":"0","endTime":"0","summary":"Citi issued a research report stating that Sino Biopharmaceutical (01177), through its subsidiary Chia Tai Tianqing, has entered into a strategic partnership with German pharmaceutical company STADA...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","C","LU0310800965.SGD","TFNS","FTXO","LU0203345920.USD","LU1074936037.SGD","LU1201861249.SGD","XPH","BK1515","LU1244550577.SGD","LU1162221912.USD","LU2125154935.USD","LU2272731865.HKD","01177","LU2236285917.USD","LU0648001328.SGD","LU2462157665.USD","LU0980610538.SGD","PPH","LU0130517989.USD","BK4566","BK4207","LU2125154778.USD","IE00BSNM7G36.USD","LU0128525689.USD","LU0203347892.USD","LU0314106906.USD","LU0130102774.USD","LU2272731600.USD","IYF","LU0170899867.USD","LU1244550494.USD","LU2322448957.HKD","IBB","BK1521","BK4534","BK4559","BK1191","BK4585","LU0098860793.USD","LU0320765646.SGD","LU1267930227.SGD","LU1668664300.SGD","LU2417539215.USD","LU2456880835.USD","LU2473716301.USD","LU0477156953.USD","BK1589","LU0106831901.USD","LU0052756011.USD","LU0162691827.USD","BK4588","LU0072461881.USD","IE00B5TLWC47.USD","LU1366192091.USD","LU2322448791.USD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1144417596.USD","BK4504","LU1791807156.HKD","LU1992135472.HKD","LU1992135399.USD","LU2272731782.SGD","IE00BZ08YR35.GBP","HK0000165453.HKD","LU1506573853.SGD","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140639624","title":"AH Premium Statistics for September 29","url":"https://stock-news.laohu8.com/highlight/detail?id=1140639624","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140639624?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:21","pubTimestamp":1790670095,"startTime":"0","endTime":"0","summary":"As of the market close on September 29, NE ELECTRIC (00042), ZHEJIANG SHIBAO (01057), and HOLLY FUTURES (03678) ranked as the top three stocks by AH premium rate, with premium rates of 1155.81%,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0488056044.USD","03188","LU1048596156.SGD","LU0049853897.USD","LU0359201885.HKD","LU1720050803.USD","LU0164880469.USD","LU0329678170.USD","LU0320764755.SGD","BK1170","IE00B031J352.USD","02359","LU0345780521.USD","LU0708995583.HKD","LU1960683339.HKD","03750","BK1148","LU2476274308.USD","LU0449509016.USD","LU0828238088.HKD","83188","LU2177674079.SGD","LU1008478684.HKD","LU0348816934.USD","LU0096374516.USD","LU2097828631.EUR","LU0043850808.USD","LU0543330566.HKD","LU1244550577.SGD","LU1226287529.USD","LU2399975544.HKD","LU0320764599.SGD","HK0000320223.HKD","LU1504937902.USD","LU0067412154.USD","LU0456846285.SGD","BK1181","LU0327786744.USD","BK1505","LU0672654166.SGD","LU1719994722.HKD","BK1198","LU0326950275.SGD","BK1562","LU0516423091.SGD","LU2242644610.SGD","BK1149","LU2476274720.SGD","LU0149534421.HKD","159982","LU1188198961.HKD","BK1191","BK1147","LU0266512473.USD","LU0048580855.USD","BK1576","HK0000352382.USD","LU0229945570.USD","82843","LU0348767384.USD","LU0828237940.HKD","LU1206782309.USD","LU1675838814.USD","IE00B031HY20.USD","03328","BK1594","LU0117841782.USD","IE00B29SXG58.USD","LU1993786604.SGD","LU0828237510.HKD","LU1282649067.USD","IE00BZ08YR35.GBP","LU0348825331.USD","IE0031814852.USD","BK1237","LU0165289439.USD","LU1251922891.USD","LU0173614495.USD","BK1515","BK1130","BK1546","LU0417516902.SGD","LU0737861699.HKD","LU0181495838.USD","02218","LU0163747925.USD","LU0345780281.USD","LU1242518857.USD","LU0244354667.USD","IE00BZ08YS42.EUR","LU0509642566.USD","00991","00568","02822","LU1303224171.USD","BK1583","LU0417516738.SGD","SG9999004220.SGD","LU1244550221.USD","LU0328353924.USD","02899","LU1880383366.USD","SG9999001226.SGD","LU0648948544.HKD","82846","LU0823426480.USD","LU1105468828.SGD","IE00BF5LJ272.USD","LU0287142896.SGD","LU0329678337.USD","LU2097828805.USD","LU0791591158.USD","HK0000306685.HKD","HK0000320264.USD","BK1202","LU0871576103.HKD","BK1183","SG9999002463.SGD","02691","02701","LU1244550494.USD","BK1190","LU1064131342.USD","06067","LU0164939612.USD","03996","LU0979878070.USD","02827","LU0531971595.HKD","LU1808992512.USD","LU0082770016.SGD","BK1554","BK1249","IE00BVYPNQ40.USD","LU1242518931.SGD","LU0791590937.USD","LU2097828557.USD","HK0001040168.HKD","IE00B3M56506.USD","399300","LU0516423174.USD","LU0072913022.USD","LU0502904849.HKD","06821","07233","LU0370786039.SGD","BK1105","LU0266512127.USD","BK1231","LU0918141887.USD","SG9999001093.SGD","IE00BYV24P56.USD","LU0214875030.USD","BK1193","LU0315179316.USD","LU0348766576.USD","LU0543330483.HKD","03678","LU0051755006.USD","LU0128522157.USD","LU1794554557.SGD","LU1115378108.SGD","LU0589944569.HKD","LU0540923850.HKD","LU0348735423.USD","LU0149721374.USD","BK1564","BK1122","LU2045819591.USD","LU2097828714.EUR","EWH","LU0607220059.USD","LU0797268264.HKD","LU1807302812.USD","LU0862451753.SGD","LU0348814723.USD","LU0231483743.USD","LU0082770016.USD","LU2125910500.SGD","LU0106959298.USD","LU1282648689.USD","LU3063872942.SGD","SG9999011746.SGD","82822","BK1119","LU0254981946.USD","LU1988902786.USD","LU0823426308.USD","BK1144","03228","LU0061477393.USD","BK1507","06185","SG9999014674.SGD","IE00BMCWC346.EUR","LU2226246903.HKD","82823","LU1366334578.USD","BK1574","00553","09976","LU0620787316.HKD","02865","IE0032431581.USD","LU0588546209.SGD","LU0455707207.USD","00187","LU0029875118.USD","LU1769817096.USD","LU0269904917.USD","BK1610","LU0463099449.HKD","03986","LU1224709979.USD","LU1255011170.USD","BK1223","LU1282649141.HKD","BK1125","LU0052750758.USD","LU0039217434.USD","02846","BK1522","BK1141","LU0918141705.HKD","LU0561508036.HKD","BK1592","02238","LU1152091168.USD","LU0880133367.SGD","HK0000306701.USD","LU1655091616.SGD","LU1770034418.SGD","LU1046422090.SGD","SG9999002828.SGD","BK1539","LU0456854461.SGD","LU0516422952.EUR","LU1769817179.HKD","IE00BVYPNP33.GBP","BK1163","LU2778985437.USD","LU0890818403.SGD","BK1161","LU0384037296.USD","LU0456827905.SGD","LU0572944931.SGD","LU0469268626.HKD","LU1023057109.AUD","LU1481107354.HKD","LU0431992006.USD","02338","03200","LU0228659784.USD","LU2008162690.USD","BK1116","LU0868486357.SGD","02843","06951","BK1551","BK1530","BK1521","IE0034224299.USD","LU0821914370.USD","LU0307460666.USD","BK1514","03308","LU0640798160.USD","02823","IE0008368742.USD","LU0164865239.USD","LU0737861772.HKD","LU0348805143.USD","06127","LU0501845795.SGD","00811","LU2039709279.SGD","03130","HK0000352291.HKD","LU0634319403.HKD","IE00BGHQDM52.EUR","HK0001040143.USD","LU1813983027.USD","LU2294711473.HKD","BK1533","01033","LU1961090484.USD","IE0008369823.USD","LU0228367735.SGD","LU0531970944.HKD","LU1211504680.USD","LU0348827113.USD","02475","01349","LU0516422440.USD","SG9999006597.SGD","BK1544","BK1110","LU0314109678.HKD","LU1688375341.USD","01108","00042","LU0211977185.USD","LU0593848301.USD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","LU1880383440.USD","LU0516422366.SGD","BK1560","LU1366334651.USD","LU2097828474.EUR","LU0886674414.USD","01812","03143","LU0140636845.USD","BK1171","83130","LU0210526637.USD","03968","LU0359201612.USD","LU1328277881.USD","IE00B543WZ88.USD","LU0348788117.USD","LU0359202008.SGD","LU1152091754.HKD","LU2264538146.SGD","LU1831875114.USD","LU0106252389.USD","01057","LU1282649810.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671829440","title":"Sino Biopharm Unit CTTQ Presents Phase 3 APEX-Breast01 Data for Tqb2102 in HER2-Low Breast Cancer at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671829440","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671829440?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:13","pubTimestamp":1790669582,"startTime":"0","endTime":"0","summary":"Sino Biopharm unit CTTQ presents phase 3 APEX-Breast01 data for TQB2102 in HER2-low breast cancer at ESMO 2026Sino Biopharmaceutical unit CTTQ will present new oncology trial data at ESMO 2026 in Madr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL88pxtq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","IE00BZ08YT58.USD","01177","BK1515","BK1521","BK1191","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671996392","title":"Sisram Medical Proposes New Sublicensing, Promo Services Pacts with Fosun Pharma's Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2671996392","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671996392?lang=en_us&edition=fundamental","pubTime":"2026-09-29 15:09","pubTimestamp":1790665781,"startTime":"0","endTime":"0","summary":"Sisram Medical Ltd  said it plans to enter into new one-year sublicensing and promotional services contracts with Fosun Wanbang  capped at $15 million, according to a Monday bourse filing.The company said its similar previous contracts will expire at the end of the year and the new contracts, if approved by the board at a special meeting, will run through 2027.Shares were last down 2% in Tuesday afternoon trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK1593","01696","BK0096","BK0183","02196","BK1100","BK1585","BK0060","BK0239","BK1515","BK0196","BK1191","BK0175","BK0187","600196","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671295721","title":"Ping An Healthcare to Renew Agreements with Ping An Life Insurance","url":"https://stock-news.laohu8.com/highlight/detail?id=2671295721","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671295721?lang=en_us&edition=fundamental","pubTime":"2026-09-29 14:27","pubTimestamp":1790663256,"startTime":"0","endTime":"0","summary":"Ping An Healthcare and Technology Company  said its board has proposed to renew certain agreements with its parent-affiliated company, Ping An Life Insurance Co. of China, originally signed in 2023, according to a Monday Hong Kong bourse filing.The healthcare platform operator said it will issue a circular with final details of the agreement, including an independent board committee's recommendation and financial advisor Gram Capital's opinion on the proposed renewal, on or around Nov. 9.Ping An Healthcare's shares were last up 5% in Tuesday afternoon trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1615","XBI","LU0128526141.USD","BK1617","LU0029874061.USD","BK1515","BK4137","BK1247","01833","BK4581","BK1219","BK1571","PAImain","BK4585","HCSG","BK1142","XLV","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293640","title":"Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293640","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671293640?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:39","pubTimestamp":1790660392,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  said its oral small-molecule IL-17A inhibitor ASC50 showed positive results in a 28-day proof-of-concept clinical trial in the U.S. for patients with mild-to-moderate plaque psoriasis, according to a Tuesday filing with the Hong Kong bourse.The once-daily 200 mg treatment achieved a 48.9% placebo-adjusted reduction in psoriasis area and severity index, or PASI, score after 28 days.The reduction increased to 60.7% six days after the final dose and 65.9% 15 days after the final dose, the filing said.The treatment was safe and well tolerated, with all adverse events reported as mild and transient.Shares of the pharmaceutical firm were down nearly 2% in Tuesday morning trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","BK1161","01672","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156162380","title":"GENFLEET-B (02595) Shares Surge Nearly 8% in Early Trading; Investigational Oral Drug Proposed for Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1156162380","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156162380?lang=en_us&edition=fundamental","pubTime":"2026-09-29 11:31","pubTimestamp":1790652676,"startTime":"0","endTime":"0","summary":"GENFLEET-B (02595) climbed nearly 8% in morning trading. As of press time, the stock was up 5.47% at HK$28.9, with turnover of HK$37.7862 million.On the news front, the company's self-developed oral...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1515","02595","KCAI","BK4588","VXUS","09939","159938","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188705505","title":"Sino Biopharmaceutical Jumps Nearly 4% as Subsidiary Strikes Strategic Biosimilar Deal with STADA, Securing Up to EUR53 Million in Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=1188705505","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188705505?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:03","pubTimestamp":1790647387,"startTime":"0","endTime":"0","summary":"Shares of Sino Biopharmaceutical (01177) climbed nearly 4%, rising 3.64% to HK$5.695 as of press time, with turnover reaching HK$89.7588 million.On the news front, Sino Biopharmaceutical announced...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FXE","MEURmain","LU1992135472.HKD","HK0000165453.HKD","BK1521","XPH","LU2272731600.USD","BK1191","NBIE","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU2272731865.HKD","PPH","IBB","LU2322448791.USD","BK4585","LU2473716301.USD","KCAI","IE00BZ08YT58.USD","VXUS","LU2272731782.SGD","BK1515","LU1992135399.USD","LU2322448957.HKD","EUO","BK1589","EURmain","IE00B5TLWC47.USD","BK4588","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181831156","title":"Estimating the Value of PL-5: How Much Is This Wound Infection Candidate Worth for HK-Listed Aspirant Prolytix?","url":"https://stock-news.laohu8.com/highlight/detail?id=1181831156","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181831156?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:41","pubTimestamp":1790646095,"startTime":"0","endTime":"0","summary":"Recently, Prolytix filed for a Hong Kong listing for the second time. The company's core innovative drug, pramlintide sodium spray (PL-5), has received marketing approval from the National Medical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4588","KCAI","VXUS","09939","159938","BK4585","BK1515","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130832239","title":"Prairie Pharmaceutical's Second Attempt at HKEX Listing: Cash Crunch, Billion-Yuan Redemption Liability Looming, Core Product Commercialization Faces Multiple Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=1130832239","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130832239?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:41","pubTimestamp":1790646076,"startTime":"0","endTime":"0","summary":"Recently, Prairie Pharmaceutical submitted its second main board listing application to the Hong Kong Stock Exchange, seeking to list under Chapter 18A rules. Just three months earlier, the company's...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1574","09939","BK1161","HEXmain","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671265701","title":"Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265701","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671265701?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640030,"startTime":"0","endTime":"0","summary":"Ascletis says ASC50 cuts PASI score 48.9% in 28-day U.S. plaque psoriasis studyAscletis reported positive results from a 28-day U.S. proof-of-concept trial of ASC50 in plaque psoriasis.Results were pr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL4TYPnv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01672","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108218509","title":"Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=1108218509","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108218509?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640027,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) announced positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial of ASC50 in patients with mild to moderate plaque...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1515","01477","BK1574","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671657252","title":"Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2671657252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671657252?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:00","pubTimestamp":1790640000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA8SGRHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","01672","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119842469","title":"Pharma ETF Rebounds Against the Tide as Device Giants Provide Support, Defensive Strength Draws Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=1119842469","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119842469?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:55","pubTimestamp":1790596546,"startTime":"0","endTime":"0","summary":"On September 28, A-shares underwent a deep correction, yet the pharmaceutical sector once again demonstrated resilience, with the sector as a whole significantly outperforming the broader market,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","562050","09939","159938","512170","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670923186","title":"CSPC Pharma Gets China Nod for Tumor Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670923186","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670923186?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:04","pubTimestamp":1790593465,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for SYS6077 injection from China's National Medical Products Administration.The indication for the approval is for advanced malignant tumors, a Monday Hong Kong bourse filing showed.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HK0000165453.HKD","LU1152091168.USD","01093","LU1008478684.HKD","BK1191","IE00B5MMRT66.SGD","IE0008368742.USD","LU0314109678.HKD","LU2039709279.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","SG9999004220.SGD","LU1807302812.USD","LU1226287792.SGD","LU0880133367.SGD","LU1226287875.USD","LU0067412154.USD","LU1226288253.USD","LU1328277881.USD","LU0326950275.SGD","LU0501845795.SGD","LU1960683339.HKD","IE0008369823.USD","BK1515","LU1226288170.HKD","LU1951186391.HKD","LU0315179316.USD","LU1813983027.USD","LU0140636845.USD","IE00BZ08YT58.USD","KURE","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1152091754.HKD","LU0072913022.USD","BK1521","IE00B543WZ88.USD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":120,"code":"91000000","status":"200"}]}}